Clofazimine, a lipophilic riminophenazine antibiotic, possesses both antimycobacterial and anti-inflammatory activities. However, its efficacy has been demonstrated only in the treatment of leprosy, not in human tuberculosis, despite the fact that this agent is impressively active in vitro against multidrug-resistant strains of Mycobacterium tuberculosis.
Introduction
Clofazimine, originally described in 1957, is the prototype riminophenazine antibiotic.
The primary clinical application of clofazimine since 1962 has been in the treatment of multibacillary leprosy as a component of the WHO-recommended triple drug regimen. 2 Notwithstanding its antimicrobial activity, the efficacy of clofazimine in the treatment of leprosy is attributable to both the lipophilicity and anti-inflammatory properties of this agent.
Lipophilicity enables clofazimine to accumulate in skin and nerves, while its antiinflammatory activities are potentially useful in controlling harmful erythema nodosum leprosum and reversal immunity reactions, which may complicate antimicrobial chemotherapy. [3] [4] [5] [6] .
Although impressively active against Mycobacterium tuberculosis (MTB) in vitro, including multidrug-resistant (MDR) strains of this microbial pathogen, 7, 8 clofazimine is generally considered to be ineffective in the treatment of pulmonary tuberculosis. This contention
arose from early studies that demonstrated inconsistent therapeutic activity of clofazimine in various animal models (hamsters, guinea pigs, rabbits, non-human primates) of experimental tuberculosis (TB). 9 Enthusiasm for the development of clofazimine as an anti-TB agent was also blunted by the unusual pharmacokinetic properties and side effects profile of this agent (see below), 10 further complicated by the fact that its discovery coincided with the emergence of the more potent anti-TB agents isoniazid and pyrazinamide in the early 1950s and rifampicin and ethambutol in the early 1960s. Although of low priority for several decades, the emergence of MDR and extensively drug-resistant (XDR) TB, together with advances in technology for the delivery of lipophilic drugs to target organs, has triggered renewed interest in clofazimine as an anti-TB agent. In addition, novel insights into the targets and molecular mechanisms of both clofazimine-mediated antimicrobial and antiinflammatory activity have provided the impetus for the design and development of novel riminophenazines with improved antimicrobial efficacy. 11, 12 The primary objective of the current review is to evaluate recent insights into: i) putative mechanisms of antimicrobial activity of clofazimine; ii) mechanisms of antiinflammatory immunosuppressive activity of this agent as these may modulate therapeutic efficacy in mycobacterial infections; and iii) innovations which may promote the efficient delivery of clofazimine to target organs. Of necessity, these will be preceded by a brief consideration of the pharmacokinetic and current clinical applications of clofazimine.
Clinical experiences and recommendations
Clofazimine is mainly indicated in the treatment of lepromatous leprosy, including dapsoneresistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum, and has been included as an anti-leprosy medicine in the current WHO Model
Lists of Essential Medicines for adults and children.
The literature on clinical experience with clofazimine in the treatment of especially pulmonary TB is sparse. Earlier reviews largely demonstrate uncertainty as to the efficacy of the drug in humans, and emphasize a fair degree of intolerance to long-term use. The drug is mainly recommended for use in combination with other drugs in the second-line treatment of drugresistant TB. 15, 16 Treatment of a small group of five TB patients with clofazimine in combination with linezolid and other drugs has also been described. 17 Although some degree of efficacy with these combination regimens was observed, adverse events were significant.
Even though clofazimine has no official indications for the treatment of drug-resistant TB, it is recommended by WHO as a Group 5 medicine, i.e. an agent with unclear efficacy, for use in patients with XDR TB.
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Studies in TB patients with HIV co-infection are largely lacking. Coyne et al. 19 observed that drug-drug interactions in such patients might be a potential concern, because clofazimine is a weak inhibitor of CYP3A4, and so protease inhibitor and etravirine concentrations may be increased, but no interaction studies have been undertaken. In earlier work, Chaisson et al. 20 found that the addition of clofazimine to a regimen of clarithromycin and ethambutol for
Mycobacterium avium complex (MAC) bacteraemia in AIDS patients does not contribute to the clinical response and is associated with higher mortality. The safety and effectiveness in children has not been established.
Molecular structure and antimicrobial spectrum of clofazimine
The key structural features of riminophenazines are the phenazine nucleus with an alkylimino (R-imino) group at position 2 and phenyl substituents at positions 3 and 10 of the phenazine nucleus. The alkylimino group is critical for antimicrobial activity, with varying, albeit secondary, contributions according to the number and type of halogen atoms on the phenyl substituents. 21, 22 The molecular structure of clofazimine, which has an isopropylimino group at position 2 of the phenazine nucleus, is shown in Figure 1 .
Clofazimine and other riminophenazines are active against mycobacteria, both slowly and rapidly growing, as well as most other Gram-positive bacteria in vitro, including those that are multidrug resistant, with MICs of 0.5-2 mg/L in most cases. 7, 8, [23] [24] [25] [26] [27] [28] [29] Gram-negative bacteria, on the other hand, are uniformly resistant to clofazimine. 23 As mentioned earlier, the clinical applications of clofazimine as an antimicrobial agent are extremely limited, despite impressive antimycobacterial activity in vitro. Notwithstanding its primary use as an anti-leprosy agent, clofazimine has been used with limited success in the treatment of MDR and XDR TB as a category 5 agent, 30 as well as in the multidrug therapy of infections caused by MAC, also with limited efficacy. 31, 32 Nonetheless, there has been a recent revival of interest in clofazimine, which can be attributed to the following: (i) impressive in vitro activity against MDR/XDR clinical isolates of MTB in vitro; 7, 9, 23 (ii) the extremely low frequency of drug resistance in MTB, 2 
Mechanisms of antimicrobial action
Although the exact mechanism(s) of clofazimine-mediated antimicrobial activity remains to be established, the outer membrane appears to be the primary site of action of this agent. 12, 24, 28, 29, [37] [38] [39] Putative targets include the bacterial respiratory chain and ion transporters.
Redox cycling
Because of its highly lipophilic nature and redox potential (-0.18V at pH 7), Barry et al, 1 in their original description of clofazimine, proposed that intracellular redox cycling was likely to contribute to the antimicrobial activity of this agent by a mechanism involving oxidation of reduced clofazimine, leading to generation of the antimicrobial reactive oxygen species (ROS), superoxide and hydrogen peroxide. 
Membrane destabilization and dysfunction
Van Rensburg et al., 25 who originally reported on the selectivity of clofazimine for
Gram-positive bacteria, including mycobacteria, proposed a mechanism of antimicrobial activity caused by disruption of membrane structure and function. We originally proposed that clofazimine-mediated enhancement of microbial phospholipases, resulting in increased generation of anti-proliferative lysophospholipids, was likely to underpin the anti-bacterial activity of this agent. 25, [37] [38] [39] However, this proposed mechanism can be discounted on the basis of two lines of evidence. Firstly, no genes encoding conventional A-type phospholipases have been documented in the MTB genome, in contrast to several putative C-type phospholipases (plc A, B, C, D). 42 Secondly, a mutant of MTB deficient in all four plc genes displayed a level of sensitivity to clofazimine equivalent to that of the wild-type strain. 43 While these findings appear to eliminate microbial phospholipases as putative mediators of the antimicrobial activity of clofazimine, they certainly do not exclude membrane destabilization, or even the involvement of lysophospholipids.
This contention is based on the study by Baciu et al, 45 who reported that cationic amphiphiles such as clofazimine partition rapidly to the polar-apolar region of the membrane, where, at physiological pH, the protonated groups on the drug catalyse the acid hydrolysis of the ester linkage of the phospholipid chains. 44 The consequence is production of a fatty acid and a lysophospholipid, both of which possess antimicrobial activity. 
Pharmacokinetic properties
Because of its lipophilicity, clofazimine is administered as a microcrystalline suspension in an oil-wax base in order to improve absorption. 51 In humans, the absorption of orally administered drug varies considerably (45%-62%) depending on whether the drug is taken with or without food. Ingestion of a 200 mg tablet taken with food resulted in a peak plasma concentration of 0.41 mg/L, with a time to C max of 8 h; without food the corresponding peak plasma concentration was 30% less, while the time to C max was 12 h. 52 Administration by the oral route of 100, 300 or 400 mg clofazimine daily to leprosy patients resulted in average plasma levels of 0.7, 1.0 and 1.41 mg/L, respectively, 51 while peak serum levels of 4 mg/L were reported following daily intake of 600 mg of this agent. 52 As mentioned above, the limited activity of clofazimine against MTB in humans may be due to inadequate peak drug concentrations or an insufficient total dose as a result of low oral bioavailability and gastric intolerance. 53 Because of its lipophilicity, clofazimine distributes primarily into fatty tissues, as well as cells of the mononuclear phagocyte system, 9 and following administration of clofazimine to mice at a dose of 25 mg/kg body weight for 28 days, the average concentrations of this agent in the lungs, spleen, fat and plasma were ∼800, 4000 and 80 mg/kg and 3 mg/L, respectively.
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In man, the concentration of clofazimine in the fat of leprosy patients has been reported to be as high as 5.3 mg/g, while concentrations of >1 mg/g were found in bile, gall bladder, kidney, pancreas, skin, liver, spleen, lymph nodes, eyes and lung. 54 .
Adverse effects
The adverse effects of clofazimine have been reported in detail elsewhere, 10,55 and are generally dose related, primarily affecting the skin, eyes and gastrointestinal tract. 10 Though tolerable, but not necessarily acceptable, reddish-brown discolouration of the skin and conjunctiva are gradually reversible on cessation of therapy. Gastrointestinal tract side effects may be mild to moderate (abdominal/epigastric pain, nausea, diarrhoea, vomiting, gastrointestinal intolerance), or, less frequently, severe (splenic infarction, bowel obstruction, bleeding), and occasionally fatal. 10 Clofazimine crosses the placenta 56 and, albeit in very small amounts, the blood-brain barrier. 54 Importantly, clofazimine is not teratogenic/mutagenic 55, 57 and does not possess myelosuppressive properties. 55 
Analogues of clofazimine
Two major strategies are being used in an attempt to increase the antimycobacterial potency of clofazimine in the setting of improved safety, namely, the development of: (i) analogues of clofazimine; and (ii) drug delivery systems.
In the case of analogue development, the late Dr J. F. O'Sullivan, a medicinal chemist and member of the Trinity College, Dublin team that originally developed clofazimine, designed and synthesized hundreds of analogues of clofazimine based primarily on varying the alkylimino substituents at position 2 of the phenazine nucleus, as well as the numbers, types and positions of halogen atoms on the phenyl substituents. The most promising of these were the tetramethylpiperidyl (TMP) derivatives, first described in the late 1980s, in which the isopropyl alkylimino group of clofazimine was replaced with the TMP group. 21 Apart from being equivalent to, or slightly superior to clofazimine with respect to antimycobacterial activity, 21, 22, 58, 59 these agents were reported to have the following advantages over clofazimine: (i) they cause less skin discolouration because they are not taken up by body fat; (ii) they do not crystallize within macrophages, potentially decreasing their half-life in the body; and (iii) they accumulate in tissues at higher levels than clofazimine. 58, 59 Unfortunately, however, these novel TMP-phenazines were described at a time when the global impact of the HIV pandemic and its ominous implications for the resurgence of TB, particularly in developing countries, were not fully appreciated. Consequently, there was little or no impetus for the clinical development of these agents.
Very recently, however, the Global TB Alliance, in partnership with several academic institutions, has embarked on a riminophenazine-based drug development programme in the belief that these agents show promise for treatment shortening in TB. 11 This is based on the premise that riminophenazines inhibit mycobacterial energy metabolism, an important target in slow-growing persisters. 11 Ideally, this research will identify a novel derivative with improved antimycobacterial activity, pharmacokinetics and safety profile, which can move quickly from preclinical to clinical development.
originating from Global TB Alliance-sponsored research were recently described by Yano et al. 12 and Lu et al. 60 The first of these, known as K56, is a more water-soluble form of clofazimine with comparable redox properties, in which the isopropyl group bonded to the imino nitrogen at position 2 on the phenazine nucleus is replaced by an aminoethylethoxyethoxy group. 12 This agent is currently under investigation with respect to antimycobacterial activity in vitro and in animal models of experimental TB. 12 Lu et al. 60 have described a series of 12 analogues with improved solubility, as well as pharmacokinetic and therapeutic activity in a murine model of experimental infection. Interestingly, these agents, most of which possess heterocyclic groups on the imino nitrogen at position 2 on the phenazine nucleus, are structurally similar to B669. 25, 38 This latter agent, as shown in Figure 1 , possesses a cyclohexyl group on the imino nitrogen and was found to be more potent than clofazimine against Gram-positive bacteria. Spray-drying is an alternative strategy that can be applied to improve solubility and enhance the dissolution rate and oral availability of poorly soluble drugs. 68, 69 This process dries the droplets of their volatile substance and leaves non-volatile components in the form of dry particles, with particle size, morphology, density and volatile content controlled by the drying process parameters. Moreover, spray-drying crystalline drugs typically yields drug particles in the amorphous state, usually with increased water solubility, because little additional energy is required to break up the crystal lattice during the dissolution process. 70, 71 Additional benefits of spray-drying include relatively low cost and energy-efficiency of the equipment, the possibility of continuous operation, and good control of the resulting physical properties of the dried material which can allow for the possibility of formulating for multiple delivery routes. 72 For example, spray-drying has been applied to formulate various drugs and biopharmaceuticals for inhalation. The lung has a large surface of absorption and a thin alveolar epithelium, allowing for rapid absorption, enabling a reduction in dose, Although not yet tested in animal models of experimental TB chemotherapy, spraydried amorphous, microparticle formulations of clofazimine, optimised with respect to physical properties and dissolution rates for oral and inhaled administration, have the potential to increase bioavailability and efficacy. 
Anti-inflammatory/immunosuppressive properties of clofazimine
In addition to its primary antimicrobial activity, clofazimine also possesses antiinflammatory/immunosuppressive properties which underpin the reported therapeutic efficacy of clofazimine in various non-microbial, chronic inflammatory disorders, predominantly cutaneous in origin. These have been reviewed by Van Rensburg et al. 25 and include discoid lupus erythematosus, pustular psoriasis, Melkersson-Rosenthal syndrome, necrobiosis lipoidica and granuloma annulare, as well as cutaneous lesions in systemic lupus erythematosus. 83 More recently, coincident with the identification of novel targets/mechanisms of immunosuppressive activity, it has been proposed that clofazimine holds broader therapeutic promise, encompassing non-cutaneous autoimmune disorders, such as multiple sclerosis and type I diabetes mellitus. 84 T lymphocytes in particular are sensitive to the immunomodulatory actions of clofazimine.
T-lymphocytes
Clofazimine, at concentrations comparable with peak serum concentrations attained during the chemotherapy of leprosy, has been reported to cause significant suppression of the mitogen-and antigen-driven proliferative responses of isolated T lymphocytes in vitro. 84, 85 Two major mechanisms, both targeting plasma membrane 
Reactive oxygen species (ROS) and prostaglandin E 2
In mixed leucocyte suspensions, clofazimine may indirectly interfere with the proliferation of T cells by promoting the release of ROS and E-series prostaglandins (PGs), especially PGE 2 , from bystander neutrophils and monocytes. 89 Arachidonic acid released from membrane phospholipids is the substrate for cyclooxygenase, resulting in production of PGE 2 . Following its interaction with adenylyl cyclasecoupled EP2 receptors on T cells, PGE 2 initiates the production of anti-proliferative 3'-5'-cyclic adenosine monophosphate (cAMP).Arachidonic acid is also a direct activator of the ROS-generating system of phagocytes, NADPH oxidase.
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These phagocyte-derived ROS are indiscriminate and interfere with the mitogen/antigendriven proliferation of T cells. 89 These three mechanisms of clofazimine-mediated T lymphocyte activation and proliferation are summarized in Figure 3 .
In the setting of mycobacterial infection, the secondary immunosuppressive properties of clofazimine may be detrimental or potentially beneficial. In TB patients with severe disease associated with advanced immunosuppression due to primary or acquired immunodeficiency, clofazimine-mediated interference with cell-mediated immunity may restrict the efficacy of other antimycobacterial agents. Taken together with the contention that clofazimine may be particularly effective in targeting slow-growing persisters, 11 this agent may be most efficacious if administered later, rather than earlier, in the course of antimycobacterial therapy. On the other hand, the immunosuppressive activity of clofazimine may be useful in controlling the adverse effects of therapy-associated recovery of cellmediated immunity, as previously reported in leprosy patients. [3] [4] [5] [6] This is of potential benefit in HIV-infected patients on dual highly active antiretroviral therapy (HAART)/anti-TB therapy who are vulnerable to the development of immune reconstitution inflammatory syndrome (IRIS).
Summary
The 
